MINNEAPOLIS, August 18, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that R&D Systems®, a brand of Bio-Techne, has launched its new Quantist Luminex® data analysis software. Compatible with all available Luminex xMAP® instruments, Quantist software provides fast and reliable analysis of Luminex multiplex assay data, helping researchers extract valuable insights from complex data.

The new Quantist software provides researchers with an important tool to quickly analyze dozens of analytes with improved accuracy and efficiency, including the ability to assess the long-term consistency of their Luminex assay data. The intuitive software interface allows users to easily perform inter-assay comparisons, adjust standard curve parameters, and export optimized data to create graph-ready Excel files.

The ability to accurately analyze complex scientific data and turn it into actionable insights is essential in all areas of research,” said Will Geist, President of Bio-Techne’s Protein Sciences Segment. “Quantist helps address this fundamental need, enabling researchers to uncover valuable insights that can accelerate discovery. It also provides an important element in our ongoing strategy of supporting customers with end-to-end solutions in their multiplex analysis workflow..”

Luminex xMAP technology is a bead-based assay platform that enables simultaneous detection of multiple targets in a single sample. Quantification of multiple cytokines and other biomarkers in a sample provides critical information about biological processes and disease. With Quantist software, R&D Systems Luminex users now have a complete, end-to-end workflow solution for intelligent, high-performance multiplexing.

Taken together, the R&D Systems® Discovery and High Performance assays make up one of the largest and most flexible Luminex analyte menus available. Tests are available for humans, mice, pigs, non-human primates and rats from samples including serum, plasma and cell culture media.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products facilitate scientific research into biological processes as well as the nature and evolution of specific diseases. They contribute to drug discovery efforts and provide the means to perform accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne has generated approximately $1.1 billion of net sales in fiscal year 2022 and has approximately 3,000 employees worldwide. For more information about Bio-Techne and its brands, please visit

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David ClaireVice President, Investor Relations
[email protected]

SOURCE Bio-Techne Corporation

Comments are closed.